Breaking down your oral presentation into specific content-related and delivery-related domains can help you remember what to rehearse and what to include.
June 2020
Peter J. DeMaria, MD and Jennifer J. Gao, MD shed light on how graduating fellows seeking a rewarding and intellectually challenging career on the frontier of cancer drug development could be well served to consider a position of federal service at the NIH or FDA.
Increasingly, patients are asking oncologists for guidance and recommendations for the use of medical marijuana. However, finding those answers is challenging because of the federal government.
Richard J. Bleicher, MD, discusses the importance of working closely with a mentor, avoiding burnout, and what to do if your interests change during your fellowship.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5